
The speakers highlight emerging trends in GLP-1 therapy, including personalized dosing, weight maintenance, combination treatments, and global innovations shaping the future of obesity management.
Dr. Juliana (Judith) Hey-Hadavi is an internationally recognized physician-executive with over 20 years of leadership experience in global medical affairs, clinical innovation, and drug development (Phases I-IV). Board-certified in Internal Medicine and Endocrinology, she brings a distinct perspective of scientific rigor, operational excellence, and visionary leadership to the advancement of therapies across diverse therapeutic areas. Her expertise spans CVMET (incl. obesity, diabetes, MASH, dyslipidemia, growth disorders, acromegaly), Neurology (stroke, Alzheimer’s disease), Immunology & Inflammation (rheumatoid arthritis, lupus, aplastic anemia, asthma), and Hospital Sterile Injectables.

The speakers highlight emerging trends in GLP-1 therapy, including personalized dosing, weight maintenance, combination treatments, and global innovations shaping the future of obesity management.

Judith Hey-Hadavi and Nicole Snow explore GLP-1 drug shortages, the safety and regulation of compounded alternatives, and strategies for patient education and proper administration to ensure effective and safe therapy.

Judith Hey-Hadavi and Nicole Snow discuss staying current on GLP-1 research and managing therapy side effects to support patient outcomes.

Judith Hey-Hadavi and Nicole Snow discuss GLP-1 receptor agonists, emphasizing personalized dosing, side effect management, and lifestyle support to optimize weight loss and patient outcomes.

This episode examines the pharmacologic basis of GLP-1 adverse reactions, dose titration strategies, and patient-specific factors shaping therapy safety.

In the second episode of our GLP-1 Therapy Insights series, experts Judith Hey-Hadavi from Worldwide Clinical Trials and Nicole Snow from Olympia Pharmaceuticals discuss the evolution of GLP-1 receptor agonists from protein-based therapies to small-molecule options.

Explore GLP-1 receptor agonists with experts Judith Heij-Hadavi and Nicole Snow: molecular design, patient care, oral therapies, and analytical insights.